Cytomedix gets $13M in RDO

Cytomedix says it has landed approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements. The company is developing regenerative therapies for wound care, inflammation and angiogenesis. Cytomedix release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.